THE RHYTHM
Weekly thiamine with retatrutide: the research rationale
Retatrutide supplies weekly pharmacological exposure. Reta-B1 investigates whether a thiamine replenishment component can be integrated into the same weekly administration event. It does not yet claim sustained seven-day thiamine release.
The administration event as the carrier
Once-weekly subcutaneous retatrutide creates a recurring, predictable point of contact between the therapy and the individual. If thiamine status warrants attention throughout a course of potent appetite suppression — the position of the 2025–2026 consensus and advisory literature — then attaching the nutritional component to the event that already happens every week is architecturally coherent: no separate pill schedule, no separate adherence problem, no gap between the pharmacology and the monitoring philosophy.
Replenishment pulse or sustained release?
Reta-B1 is a replenishment-pulse hypothesis, not a depot. A weekly 20 mg thiamine component, reconstituted and administered with the peptide, would deliver a discrete weekly quantity of a water-soluble vitamin. Whether such a pulse meaningfully supports thiamine status across a treatment course is an empirical question with a defined readout — whole-blood thiamine pyrophosphate and erythrocyte transketolase activity — not an assumption built into the name. Any future claim of sustained seven-day release would require dedicated release-profile data that do not currently exist.
The open questions
- Does a weekly thiamine component measurably support thiamine status during retatrutide-class exposure?
- Does co-formulation affect retatrutide pharmacokinetics or activity — in either direction?
- What does post-reconstitution compatibility look like across the intended hold time?
- Is subcutaneous local tolerance acceptable for the combined preparation?
Each question maps to a named pillar of the Reta-B1 testing programme. Until the data exist, the weekly concept is exactly what this page calls it: a research rationale.